Key Capital Fast-tracking Breakthrough Liver Cancer Immunotherapy
FDA Orphan Drug Designated Immunitor V5 Development to be Accelerated Key Capital Corporation (OTCMKTS:KCPC) The sooner that we can achieve FDA approvals, the quicker we will be able to offer…